



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/890,936	11/07/2001	Olle Korsgren	KORSGREN-1	9165

1444 7590 08/25/2003

BROWDY AND NEIMARK, P.L.L.C.
624 NINTH STREET, NW
SUITE 300
WASHINGTON, DC 20001-5303

EXAMINER

JAGOE, DONNA A

ART UNIT	PAPER NUMBER
----------	--------------

1614

DATE MAILED: 08/25/2003

7

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/890,936

Applicant(s)

KORSGREN ET AL.

Examiner

Donna Jagoe

Art Unit

1614

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on 27 May 2003.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-11 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-11 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some * c) ☐ None of:
1. ☒ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____
- 4) ☐ Interview Summary (PTO-413) Paper No(s). _____
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: _____

Art Unit: 1614

Claims 1-11 are pending in this application.

Response to Amendments

Objection of claims 8 and 9 is no longer maintained in view of the amendments.

Rejection of claims 1-9 under 35 USC §112 2nd paragraph is no longer maintained in view of the amendments.

Rejection of claims 1-10 under 35 USC 101 is no longer maintained in view of the amendments.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-10 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. Claims 1 and 10 contain subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. Applicant has added a proviso that the isolated islets are not artificially encapsulated. This is new matter since it is not described in the instant specification.

The remaining claims are indefinite to the extent that they read on the rejected base claims.

Response to Arguments

Applicant's arguments filed 27 May 2003 have been fully considered but they are not persuasive. The rejection made in paper number 5 over Wagner et al. under 35 U.S.C. §102(b) is maintained and is hereby repeated.

Applicant asserts that Wagner teaches microencapsules used in transplantation surgery. The abstract for Wagner et al. teach that the immobilized material is insulin, proinsulin and/or organ cells of xenogenic or autogenic origin (islets of Langerhans, etc.) and the system contains an agent to inhibit or suppress blood agglutination, agglomeration antagonists, heparin, hirudin, marcumar and their derivatives. Wagner discloses that the islets *may* be microencapsulated. Additionally, if the cells are microencapsulated, they are first mixed with the anticoagulant material, thus anticipated the claims of the instant application.

The rejection made in paper number 5 over Lenchow et al. under 35 U.S.C. §102(b) is maintained and is hereby repeated.

Applicant asserts that while Lenchow does describe the use of human islets for transplantation, and additionally uses an immunoglobulin G1Fc, that Lenchow does not address the coagulation process. Applicant is reminded that prevention of clotting is not claimed. Applicant has claimed a method of transplanting insulin-producing cells wherein the cells are coated with a clotting preventing agent. Since the immunoglobulin G1Fc is a clotting preventing agent, and it is administered with the islet cells, it anticipates the claims.

Art Unit: 1614

The rejection made in paper number 5 over Soon-Shiong et al. under 35 U.S.C. §102(b) is maintained and is hereby repeated.

Applicant asserts that the instant invention does not involve and applicants do not claim microcapsules as disclosed by Soon-Shiong et al. However, upon examination of the instant specification, applicant describes immobilizing heparin according to a method developed by Corline Systems AB disclosed in WO 93/05793 (page 4 of the instant specification). The heparin in WO 93/05793 appears to be immobilized (conjugated) with a polymer comprising a substantially straight-chained organic homo or hetero polymer having a number of functional groups distributed along the polymer backbone chain via which groups at least about 20 molecules (see page 7 of WO 93/05793). While applicant asserts that the heparin is not in microcapsules, it appears that it is similarly coated and as such, must form micro (or macro) capsules if applicant has followed the technique of Corline Systems AB.

The rejection made in paper number 5 over Soon-Shiong et al. under 35 U.S.C. §103(a) is maintained and is hereby repeated.

Applicant asserts that Soon-Shiong does not disclose use of a clot-preventing agent to produce a drug for transplantation of insulin producing cells in the form of isolated islets to patients with insulin dependent diabetes mellitus wherein the inhibitor is an inhibitor of platelet activation. The reference discloses therapeutic applications such as the encapsulation of islets of Langerhans for the treatment of diabetes (column 3, line 65 to column 4, line 1). It would have been obvious to one of skill in the art to substitute an agent that inhibits platelet activation for an agent such as heparin that inhibits thrombin

Art Unit: 1614

since the end result of both agents is to inhibit a blood clot. It is prima facie obvious to substitute equivalents, motivated by the reasonable expectation that the respective species will behave in a comparable manner or give comparable results in comparable circumstances. *In re Ruff* 118 USPQ 343; *In re Jezel* 158 USPQ 99; the express suggestion to substitute one equivalent for another need not be present to render the substitution obvious. *In re Font*, 213 USPQ 532.

Regarding the information disclosure statement referred to on page 8 of the previous office action, while it is noted that the IPER is included in the file, it is not a proper information disclosure statement as pointed out in the previous office action. If applicant wishes the documents to be considered, applicant must list the documents on a PTO form 1449 and provide a copy of each non-U.S. Patent publication.

Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of

Art Unit: 1614


the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Correspondence


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Donna Jagoe whose telephone number is (703) 306-5826. The examiner can normally be reached on Monday through Friday from 8:00 A.M. - 4:30 P.M..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Seidel can be reached on (703) 308-4725. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.


Donna Jagoe
Patent Examiner
Art Unit 1614

dj


WAYNE JONES
PRIMARY EXAMINER